NCT03690011View on ClinicalTrials.gov

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2040

Conditions
T-cell Acute Lymphoblastic LymphomaT-non-Hodgkin LymphomaT-cell Acute Lymphoblastic Leukemia
Interventions
GENETIC

CD7.CAR/28zeta CAR T cells

"Three dose levels will be evaluated:~* Dose level one: 1×10\^7 cells/m\^2~* Dose level two: 3×10\^7 cells/m\^2~* Dose level three: 5x10\^7 cells/m\^2~* Dose level four: 1×10\^8 cells/m\^2"

Trial Locations (2)

77030

RECRUITING

Houston Methodist Hospital, Houston

RECRUITING

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Leukemia and Lymphoma Society

OTHER

collaborator

Cancer Prevention Research Institute of Texas

OTHER

lead

Baylor College of Medicine

OTHER

NCT03690011 - Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells | Biotech Hunter | Biotech Hunter